Gonadotropin hormone releasing hormone agonists [GnRHA] and prevention of familial breast cancer.
The use of GnRHA to induce a "medical" oophorectomy may be a useful method of prevention of breast carcinoma. The addition of ERT and intermittent progestogen to the GnRHA would be expected to prevent the adverse effects of estrogen deprivation, and still provide a significant reduction in breast cancer risk. Evaluation of the regimen in a high risk group such as sisters or daughters of index cases of early onset breast cancer is justifiable.
Spicer
D
D
Kenneth Norris Jr. Comprehensive Cancer Center, Los Angeles, CA 90033.
Pike
M
M
Lobo
R
R
Paganini-Hill
A
A
Richardson
J
J
Dworsky
R
R
Weaver
F
F
D000328:Adult; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D010865:Pilot Projects; D011372:Progestins / Q000627:therapeutic use; D011966:Receptors, LHRH / Q000187:drug effects*; D012307:Risk Factors; D015983:Selection Bias
D011372:Progestins; D011966:Receptors, LHRH